Success Metrics

Active Trials
5(45%)

Phase Distribution

Ph phase_1
4
36%
Ph phase_2
5
45%
Ph phase_3
2
18%

Phase Distribution

4

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
5(45.5%)
Phase 3Large-scale testing
2(18.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Other(3)

Detailed Status

Recruiting4
Not yet recruiting3
unknown2
Suspended1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
5
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 14 (36.4%)
Phase 25 (45.5%)
Phase 32 (18.2%)

Trials by Status

recruiting436%
suspended19%
unknown218%
active_not_recruiting19%
not_yet_recruiting327%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials
NCT07720193Phase 3

A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

Not Yet Recruiting
NCT07009457Phase 1

A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

Active Not Recruiting
NCT07296809Phase 2

SKB500 Combinations in Patients With Small Cell Lung Cancer

Recruiting
NCT06157827Phase 1

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Recruiting
NCT05403723Phase 1

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Suspended
NCT07268040Phase 2

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Recruiting
NCT06792253Phase 3

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
NCT06786312Phase 2

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Not Yet Recruiting
NCT06375109Phase 2

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

Not Yet Recruiting
NCT06164327Phase 1

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Unknown
NCT04363255Phase 2

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11